Trends in the choice of antiseizure medications in juvenile myoclonic epilepsy: A retrospective multi-center study from Turkey between 2010 and 2020


Kilic B., SERDAROĞLU E., Polat B. G. , Ince T., ESENÜLKÜ G., Topcu Y., ...More

SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, vol.99, pp.48-53, 2022 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 99
  • Publication Date: 2022
  • Doi Number: 10.1016/j.seizure.2022.05.005
  • Journal Name: SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
  • Journal Indexes: Science Citation Index Expanded, Scopus, CINAHL, EMBASE, MEDLINE, Psycinfo
  • Page Numbers: pp.48-53
  • Keywords: juvenile myoclonic epilepsy, valproic acid, levetiracetam, LEVETIRACETAM, VALPROATE, MONOTHERAPY, MANAGEMENT

Abstract

Purpose:Valproic acid (VPA) is frequently used and effective in juvenile myoclonic epilepsy (JME). Recently, levetiracetam (LEV) has been suggested as a monotherapy in JME. This study aimed to evaluate antiseizure medication (ASM) use in patients with JME.